Cytosorbents Corp — Director's Dealing 2021

Sep 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cytosorbents Corp (CTSO)
CIK: 0001175151
Period of Report: 2021-08-31

Reporting Person: Kraus Al (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-31	Common Stock	M	4000	$4.125	Acquired	129046	Direct
2021-08-31	Common Stock	S	4000	$9.3978	Disposed	125046	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-31	Stock Option (right to buy)	$4.125	M	4000	Disposed	2022-01-18	Common Stock (4000)	Direct

Footnotes

F1: Reflects the weighted average price of sales on August 31, 2021. The shares were sold in multiple transactions at prices ranging from $9.38 to $9.409, inclusive. The reporting person undertakes to provide to CytoSorbents Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F2: Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 55,746 shares of common stock owned by the reporting person.